Isomorphic Labs, the London-based artificial intelligence drug design company spun out from DeepMind in 2021, has closed a $2.1 billion Series B financing round led by Thrive Capital, with participation from Alphabet, GV, CapitalG, Temasek, and Abu Dhabi’s MGX. The round brings total capital raised by the company to approximately $2.6 billion and establishes a new high-water mark for private investment in computational drug discovery.
The company’s scientific identity is inseparable from AlphaFold, the protein structure prediction system that upended structural biology when it demonstrated near-experimental accuracy in predicting protein folding from amino acid sequence alone. AlphaFold3, released by DeepMind and Isomorphic in 2024, extended those capabilities to predict the structure of protein-ligand, protein-nucleic acid, and protein-protein complexes — an advance that fundamentally changes how medicinal chemists think about hit identification and lead optimisation.
Isomorphic’s proprietary IsoDDE (Integrated Structure-based Drug Design Engine) wraps these prediction capabilities into an end-to-end pipeline that can propose, score, and prioritise novel small molecules against a defined target in a matter of days rather than the months typical of traditional structure-based campaigns.
Until now, Isomorphic had released limited detail on its internal pipeline, preferring to operate its research partnerships with Eli Lilly and Novartis — both announced in 2024 for combined milestone-eligible deals worth over $3 billion — as the primary commercial proof of the platform. The Series B announcement shifted that posture. The company confirmed it now has multiple proprietary candidates in late preclinical development and expects to file at least one Investigational New Drug application before the end of 2026.
The IND filing, if achieved on schedule, would mark a categorical milestone: the first time a drug designed substantially or entirely by an AI system, with no prior human-directed medicinal chemistry campaign, enters a human clinical trial. That claim requires some nuance — all programmes at Isomorphic involve human scientists making target selection and candidate advancement decisions — but the molecule design itself is algorithmically generated.
The size and composition of the investor syndicate matters too. Temasek and MGX bring sovereign capital from Singapore and the UAE respectively, reflecting growing geopolitical interest in securing positions in foundational AI-enabled biotech infrastructure. For portfolio construction, these are patient, decade-horizon investors comfortable with clinical risk at scale.
The proceeds will fund expansion of Isomorphic’s wet laboratory capabilities in London, additional compute for IsoDDE training runs, and the clinical operations infrastructure needed to manage first-in-human trials. The company is understood to be evaluating oncology and metabolic disease as initial clinical indication areas, though no target disclosures have been made.
Whether AI-designed molecules will perform differently in Phase 1 dose-escalation studies than conventionally designed drugs is a question the field will begin to answer within the next 18 months. The data will be watched closely.
